ADC Therapeutics set to go public
Antibody drug conjugate expert ADC Therapeutics SA has filed a Registration Statement for an Initial Public Offering with the US Securities and Exchange Commission.
Author Archive for: TG
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 1185 entries already.
Entries by Thomas Gabrielczyk
iStar Medical SA raises 40.1m
/in News/by Thomas GabrielczykGlucoma transplant specialist iStar Medical SA has closed a Series C finanincing round led by LSP and Gimv.
Pro-apoptotic protein blocks autoimmunity
/in News/by Thomas GabrielczykA US-EU research team has found that a class of compounds that promote tumour cell death can also limit autoimmunity.
Sequencing-ready DNA for fast Molecular Breeding results
/in News/by Thomas GabrielczykBioEcho develops single-spin and 96-well kits for the isolation of DNA from different starting materials. Their proprietary EchoLUTION single-step technology avoids the use of inhibitory process reagents while using dedicated […]
Immatics and Celgene enter $1.5bn deal
/in News/by Thomas GabrielczykCelgene will pay $75m upfront to get an option on three cancer programmes developed by Immatics Biotechnologies.
Microbial feed company Unibio raises US$15m
/in News/by Thomas GabrielczykDanish microbiology specialist Unibio International plc had completed a US$15m financing round led by West Hill Capital.
GSK reaches endpoint in pivotal blood cancer study
/in News/by Thomas GabrielczykGlaxoSmithKline plc announced belantamab mafodotin (GSK2857916) met the primary endpoint of overall response rate (ORR) in a pivotal Phase II trial in treatment-refractive multiple myeloma.
Swiss researchers report on metastasis switch
/in News/by Thomas GabrielczykResearchers from Paul Scherrer Institute in Villingen, Switzerland, and Hoffmann La-Roche AG report in Cell they have solved the structure of a target relevant in metastasis.
Preclinical antibody stops rheumatoid arthritis
/in News/by Thomas GabrielczykAn antibody therapy that targets red blood cells (RBCs) unexpectedly showed anti-inflammatory effects and rapidly reversed rheumatoid arthritis and prevented lung injury in mouse models.
Nabriva receives FDA approval for novel antibiotics
/in News/by Thomas GabrielczykNabriva Therapeutics plc has got the go from the FDA to market its pleuromutilin antibiotic Xenleta (lefamulin), a protein synthesis blocker with new mode-of-action to treat community-acquired bacterial pneumonia.